alterations are found in BMPR1A on chromosome 10 in 20% to 25% of cases or SMAD4 on chromosome 18 in 20% to 25% of individuals. The genetic origin of JPS is unknown in 50% to 60% of cases. Hereditary hemorrhagic telangiectasia (HHT) is also an autosomal dominant disorder resulting in visceral arteriovenous malformations (AVMs) and whose susceptibility genes encode proteins in the transforming growth factor β family, to which SMAD4 and BMPR1A belong. Affected patients with HHT develop recurrent mucocutaneous and GI bleeding and have the potential for life-threatening hemorrhage owing to AVMs in other visceral organs. HHT occurs in up to 1:5000 individuals. The clinical criteria used to make a diagnosis of HHT are known as the Curacao critera. 2 The criteria include epistaxis, visceral AVMs (in the brain, lung, spine, liver, or GI tract), mucocutaneous telangiectasias, and/or a family history of HHT. A diagnosis of HHT is confirmed when ≥3 criteria are met and is suspected when 2 criteria are present. It is recommended that an individual with a family history of HHT and a personal history of a visceral AVM be diagnosed with HHT. 2 The majority of patients with HHT carry a germline alteration in one of the following 3 genes: activin receptorlike kinase 1 (ALK1) on chromosome 9, which is seen in 50%; endoglin (ENG) on chromosome 12, which is seen in 35%; or in SMAD4, which is found in the minority, 1% to 2%. 3 The coexistence of JPS and HHT as an overlapping syndrome due to a common genetic origin was first noted in the 1980s. 4 Since that time, existing literature has suggested a JPS-SMAD4 genotype HHT phenotype correlation. Aretz et al 5 studied 80 unrelated JPS patients and observed HHT in 22% of 23 unrelated SMAD4 mutationpositive patients. Importantly, patients with HHT due to a SMAD4 alteration are at risk of having JPS. 6 The overlap between these 2 syndromes may carry significant clinical implications that require recognition by the health care team managing these patients, including the gastroenterologist, colorectal surgeon, genetics professional, pulmonologist, and anesthesiologist, especially when endoscopic procedures or surgery may be required. One of our JPS-SMAD4 patients not previously screened for HHT developed hemodynamically significant atrial fibrillation at the time of induction of anesthesia for a total colectomy and ileal rectal anastomosis. The surgery was cancelled, and an echocardiogram revealed intrapulmonary shunting, which was the likely cause of the cardiac event. Within our JPS-SMAD4 mutation-positive population, we observed a seemingly higher prevalence of HHT and HHT-related complications than previously reported. 7 The aim of this study was to document the prevalence and signs and symptoms of HHT in a sample of JPS patients carrying a SMAD4 mutation from the David G. Jagelman Inherited Colorectal Cancer Registry. We also compared the colorectal and gastric polyposis phenotype between JPS patients who had SMAD4 mutations and those patients who had not undergone genetic testing.
METHODS
JPS patients were identified from a comprehensive, institutional review board-approved polyposis database with the use of Cologene software within the Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia. All JPS patients, regardless of genotype, were contacted by telephone to review their personal and family history for the symptoms and signs of HHT based on a standardized data collection sheet and a review of medical records. The HHT features queried included whether the subject had any of the following: epistaxis, mucocutaneous telangiectasias, visceral AVMs, and possible sequelae of AVMs, such as hemorrhagic stroke, brain abscess, and GI bleeding. Medical records were reviewed to confirm patient-reported information. Our registry recommends HHT-screening examinations, including physical examination for telangiectasias, agitated saline bubble echocardiogram followed by noncontrast CT scan of the chest, if the former is positive, and brain MRI/magnetic resonance angiography. The results of phone contacts, medical record review, and HHT screening were documented. Patients with 3 or more of the Curacao criteria or a family history of HHT and a visceral AVM were confirmed to have HHT. Patients with 2 manifestations were recorded as suspected of having HHT. The colorectal and gastric polypsis phenotype was graded at the time of surgery or at the last observation: mild <50 polyps, moderate 50 to 100 polyps, severe >100 polyps. A comparison of polyposis phenotype was made between JPS patients who had SMAD4 mutations and those patients who had not undergone genetic testing. For the comparison of the 2 cohorts, categorical values are presented as mean ± SD with t test or n (%) and with Wilcoxon rank sum test for polyposis severity and Pearson χ 2 test otherwise.
RESULTS
Sixty-two JPS patients belonging to 41 unrelated families were identified from our registry. Among these patients, 46 (74%) individuals were able to be contacted by telephone, 10 were unavailable, and 6 were deceased. Those not contacted by telephone had a review of their medical records only. Eighteen of the 41 JPS families had undergone genetic testing ( Fig. 1 ). Nine families carried a mutation in SMAD4, 3 had a mutation in BMPR1A, and 1 family had an interstitial deletion on chromosome 10 that encompassed BMPR1A and the PTEN gene, which resulted in juvenile polyposis of infancy. In 4 families, no mutation was detected in BMPR1A or SMAD4, and 1 family only had BMPR1A testing, which was negative, but they have not had SMAD4 testing. Twenty-three families, which includes 28 individuals, have not had genetic testing. The 9 families with a SMAD4 mutation include 21 mutation-positive individuals. These include 11 men and 10 women, with a current age of 40 years (range, 4-70). The SMAD4 mutations were found between exons 3 and 9, with the majority found in exons 8 and 9 in the MH2 domain.
Seventeen of the 21 JPS-SMAD4 patients (81%) met the Curacao criteria for HHT, and an additional 14.3% (3/21) are suspected of having HHT ( Table 1 ). One of the 3 patients suspected of having HHT has a family history of HHT and epistaxis, but has no reported AVMs and has not undergone HHT screening. The other 2 individuals suspected of having HHT have no family history of HHT, but both have at least 1 organ involvement with a visceral AVM and either telangiectasias or epistaxis.
Seventeen of 21 patients (81%) (8 women) from 7 SMAD4 families underwent prospective HHT screening at a mean age of 37 years (range, . Sixteen of the seventeen (94%) undergoing HHT screening met the Curacao criteria for HHT and one (6%) is suspected of having HHT with 2 manifestations, including epistaxis and pulmonary and brain AVMs. All but one of the individuals who underwent prospective HHT screening with imaging procedures had evidence of a visceral AVM.
HHT Manifestations
Twelve (57%) of the SMAD4 mutation-positive patients have a family history of HHT. Epistaxis is the most commonly reported HHT sign or symptom, present in 15 patients (71%), followed by telangiectasias in 12 (57%). Eighteen of 21 patients (86%) had documentation of a visceral AVM. Contrast echocardiography was the most sensitive imaging technique for pulmonary AVMs and indicated intrapulmonary shunting in 13 of 16 patients (81%) who underwent the test ( Table 2 ). The shunt was large enough to be confirmed on noncontrast CT scan of the chest in 7 of 13 (54%). Two patients underwent coil embolization of the pulmonary AVM, and the other 5 are undergoing surveillance. Nine of 10 patients with asthma had a pulmonary AVM. Conversely, 9 of 13 patients (69%) with evidence of a pulmonary AVM have asthma. A central nervous system AVM was detected in 6 of 17 patients (35%) who underwent magnetic resonance angiography of the brain. Two patients underwent coil embolization of the AVM, and 4 are undergoing surveillance.
In the 23 families that have not had genetic testing, 1 subject met 3 HHT criteria (3.6%) and 2 subjects (7%) met 2 criteria including either epistaxis, GI and pulmonary AVMs and/or telangiectasias. Of the 3 families with a BMPR1A mutation, no individual met the criteria for HHT. Of the 4 families with neither SMAD4 nor BM-PR1A detected, none of the individuals met criteria for HHT.
Polyposis Phenotype
We compared the polyposis phenotype in our SMAD4positive patient with those who have not undergone genetic testing ( Table 3 ). The mean age at JPS diagnosis in each group was the late teens to early twenties (p = 0.78). No significant difference was noted in the severity of polyposis at the time of surgery or last observation (p = 0.26), although severe colonic polyposis was more common in individuals who had not had genetic testing, 57%, versus those with a SMAD4 mutation, 24%. Colectomy was performed in 57% in each group at a mean age of approximately 22 to 23 years.
The severity of gastric polyposis was not different at the time of gastrectomy or last observation (p = 0.52). Severe gastric polyposis was noted in 9 (43%) of the SMAD4positive patients versus 10 (36%) of the untested patients. Although more than twice as many SMAD4-positive patients required a gastrectomy than the genetically untested patients, 38% versus 18% (p = 0.11), the interval between the age of diagnosis and date of gastrectomy was shorter in the genetically untested group, 23 years versus 8 years (p = 0.033). Our study included 4 individuals in 4 families that had no mutation detected in BMPR1A or SMAD4. The colon phenotype was mild in 3, who are undergoing surveillance, and severe in one, who had a rectal cancer at age 19 and underwent a colectomy. The gastric polyp phenotype was mild in all 4, and none required a gastrectomy.
DISCUSSION
JPS carries a high cumulative lifetime risk of GI cancer including colorectal in up to 68% and gastric in up to 25%. [8] [9] [10] Patients with JPS require intensive endoscopic surveillance for polyp management and cancer detection, and endoscopic intervention for GI bleeding due to intestinal AVMs, as well. As is noted from our cohort, JPS patients frequently develop serious complications of the polyposis requiring colectomy or gastrectomy. Over half of our JPS cohort required colectomy at a mean age of 22, whereas the gastric complications requiring gastrectomy occurred nearly 2 decades later. Most practitioners caring for patients with the rare polyposis syndromes are less cognizant of the "extracolonic manifestations" of the disease or fully understand the magnitude of the disease-associated risks. The additional burden and enhanced complexity of comanaging both HHT and JPS requires specialized expertise and knowledge of the surveillance requirements particular to this subset of JPS patients.
Our data demonstrate that 81% of JPS patients with a SMAD4 mutation had HHT. The proportion of patients diagnosed with JPS HHT overlap syndrome is higher than previously reported from other series. It is possible that our study detected a higher prevalence of individuals with JPS HHT overlap syndrome because we have numerous relatives from 1 large family and numerous families with the same genetic mutation. On the other hand, it may be a higher than previously reported because not all previous studies performed systematic HHT screening. In our cohort, 14% of our SMAD4-JPS patients met 2 criteria of HHT, not all of whom have had the required HHT surveillance. In addition, nearly 15% of our JPS patients who have not had genetic testing had either confirmed or suspected HHT. All of our patients at the time of genetic counseling are recommended to have genetic testing, although slightly more than half the families in our cohort have not opted for genetic testing. Those with SMAD4 mutations are advised to undergo HHT screening. Financial coverage of genetic testing and HHT screening seems to be the greatest limitation to having these performed. Given the potential serious sequelae of HHT, it is imperative that patients with JPS understand these risks at the time of genetic counseling.
The GI management of JPS is reasonably well established and depends on the severity of the polyposis. 11, 12 When the colon is severely affected or symptoms are present, total colectomy with ileorectal anastomosis (if the rectal polyp burden is mild) or proctocolectomy with IPAA (if the rectum has >20 polyps) is indicated. In asymptomatic patients or those with milder polyp burden, colonoscopy with polypectomy every 1 to 3 years depending on the polyp burden or colectomy, because of the high lifetime risk of colorectal cancer, is appropriate. As can be seen by our cohort, gastric polyposis is often severe and symptomatic, particularly in those patients with SMAD4 mutations, and may lead to gastrectomy in a significant percentage, 38% of the SMAD4 mutation carriers versus 18% of the untested patients in our series.
The presence of HHT introduces a layer of complexity to the management of JPS patients, particularly in regard to the preoperative evaluation and anesthesia-related considerations to minimize the possible complications of the procedure, sedation, and operation. Intestinal AVMs may bleed chronically, causing iron deficiency anemia, whereas pulmonary AVMs result in changes in lung physiology because of intrapulmonary shunting, or acute problems such as paradoxical embolization, cerebral abscess, and stroke. Pulmonary hypertension may be due to pulmonary or systemic arteriovenous shunting in the liver or GI tract, leading to an increase in cardiac output. Although most SMAD4-JPS patients had no clinically apparent symptoms from their AVMs, we found that asthma was a frequently associated disease in the overlap patients. The majority of the patients with pulmonary AVMs (69%) had asthma. Whether asthma is a result of pulmonary AVMs or a manifestation related to aberrancy in the transforming growth factor β/bone morphogenetic protein signaling cascade is not known. Although contrast echocardiogram detected subclinical, intrapulmonary shunting in the majority of our cohort (81%), slightly more than 50% had clinically detectable lesions on CT. Two of our patients required embolization of pulmonary AVMs (one after a brain abscess), and the rest are being monitored for changes in size or development of symptoms. Three of 6 (50%) patients with cerebral AVMs had clinically significant lesions that required embolization.
Seventy-seven percent of our families have a SMAD4 mutation that clusters in the MH2 domain of the gene between exons 8 and 11. A recent study by Gallione et al 6 showed that the majority of the mutations in their JPS HHT overlap cases were also in the same MH2 domain. Aretz and colleagues 5 documented that 82% of their SMAD4 mutation-positive patients had mutations in this domain, but they did not specify which of the patients had associated HHT. At this time, there are insufficient data to restrict screening for HHT selectively in patients with 3′-located SMAD4 mutations. Recommendations for HHT screening exist, and it has been suggested that SMAD4 mutation carriers undergo HHT screening [13] [14] [15] [16] [17] [18] ( Table 4 ). Our 3 families with a BMPR1A mutation did not have signs or symptoms of HHT or a family history of HHT, suggesting that HHT is limited to SMAD4 mutation carriers. More families with BMPR1A mutations are needed to establish this.
The minority of cases of HHT are due to a SMAD4 mutation. 19, 20 Other genes associated with HHT are ENG, encoding the cell surface coreceptor endoglin, and ACVRL1 (ALK1), also encoding a cell surface receptor. Up to 85% of patients with clinical criteria for HHT will have a mutation in one of these latter 2 genes. Only SMAD4 mutations are consistently associated with GI polyposis, so that colonoscopy and upper endoscopy screening is recommended only in HHT families with mutations in this gene. There are rare individuals presenting with mixed polyps who have ENG mutations. 21 Treatment of the manifestations of HHT includes ablation of small, accessible, symptomatic AVMs. Patients with pulmonary AVMs may have significant intrapulmonary shunting and require antibiotic prophylaxis for dental and invasive procedures in addition to a filter on intravenous lines. Long-term follow-up of patients with HHT includes yearly complete blood count and contrast echocardiography every 5 years.
Our study provides evidence that JPS-HHT overlap syndrome is more common than previously observed, 81% in our cohort. In fact, the manifestations of HHT have clinically important implications for endoscopists, surgeons, anesthesiologists, and genetic counselors. Genetic testing for SMAD4 and BMPR1A should be performed in all JPS patients in the setting of genetic counseling, and systematic HHT screening is recommended for JPS patients with SMAD4 mutations. Similarly, colonoscopy and upper endoscopy surveillance is recommended in HHT patients who have a germline SMAD4 mutation. If patients do not pursue genetic testing, but present with at least 2 manifestations of HHT, they should be kept under close surveillance to see if they develop HHT. A large multicenter study to determine whether any SMAD4-genotype, HHT-phenotype correlation can be established and what the potential effect of HHT on JPS patients would be, would be beneficial.
